- Aurinia Pharmaceuticals Inc. (AUPH, Financial) announced significant findings from the AURORA 1 study on LUPKYNIS-based therapy for lupus nephritis.
- The study demonstrated that patients receiving LUPKYNIS, alongside other therapies, achieved substantially lower proteinuria levels.
- These findings were presented at the LUPUS 2025 Congress, highlighting the potential impact on long-term kidney health and lipid profiles.
Aurinia Pharmaceuticals Inc. (AUPH) recently unveiled promising results from a comprehensive post-hoc analysis of the Phase 3 AURORA 1 study. This study showcased the effectiveness of a LUPKYNIS® (voclosporin) based triple immunosuppressive therapy in managing lupus nephritis (LN), a severe kidney disease. Researchers found that the combination of LUPKYNIS, mycophenolate mofetil (MMF), and low-dose glucocorticoids led to a remarkable reduction in proteinuria levels, a key marker of kidney health.
Among the 357 patients participating in the AURORA 1 study, a significant 60.9% in the LUPKYNIS-based therapy group attained a urine protein creatine ratio (UPCR) of ≤0.4 g/g, surpassing the 37.1% success rate in the control group, who only received MMF and glucocorticoids. This achievement in reducing proteinuria is essential, as it correlates with enhanced long-term kidney outcomes.
Additionally, further analysis of lipidomic profiles suggested potential cardiovascular benefits associated with attaining ultra-low UPCR targets. While more research is essential to understand these lipid changes, the findings imply that LUPKYNIS could play a critical role in modifying cardiovascular risks in LN patients.
The data, presented at the LUPUS 2025, emphasizes the importance of early intervention and superior management strategies in LN treatment. According to Dr. Greg Keenan, Aurinia's Chief Medical Officer, the study reinforces LUPKYNIS's critical role in reducing proteinuria levels, potentially mitigating significant kidney damage and associated comorbidities.
Aurinia continues to advocate for the therapeutic potential of LUPKYNIS (AUPH, Financial) as part of an innovative treatment regimen for lupus nephritis, underpinning its pioneering status in the biopharmaceutical industry. This development marks a significant step forward in improving health outcomes for patients living with this challenging condition.
